DERAMCICLANE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H31NO
Molecular Weight	301.4662
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C3=CC=CC=C3

InChI

InChIKey=QOBGWWQAMAPULA-RLLQIKCJSA-N

InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C20H31NO
Molecular Weight	301.4662
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19963003 | https://www.ncbi.nlm.nih.gov/pubmed/15949921 | https://www.ncbi.nlm.nih.gov/pubmed/9551765

Deramciclane is camphor derivative. It is an anxiolytic agent that binds with high affinity to 5-HT2A/2C receptor. Deramciclane showed significant evidence of efficacy for the treatment of generalized anxiety disorder in adult patients. A single dose of deramciclane was rapidly absorbed with peak plasma concentrations being reached after about 3 h. Deramciclane has a half-life of around 27 h. The most commonly reported adverse event was headache. In the in vitro studies deramciclane concentration-dependently inhibited NMDA evoked spreading depression.

Approval Year

PubMed

Title	Date	PubMed
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze.	2001 Jan	11271409
Deramciclane (Egis).	2002 Feb	12020062
Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds.	2002 Mar	11849919
In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers.	2002 Mar	11849912
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration.	2003	14584962
Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.	2003 Dec	14566442
The effect of oil as a dietary component on in vitro dissolution of an acid-labile drug.	2003 Jul	12894756
Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats.	2004 Apr	15099931
Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers.	2004 Aug	15366325
Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.	2004 Feb	14730412
Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers.	2004 Nov	15451546
Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.	2005 Dec	15949921
Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human.	2005 Nov	16118331
Role of CYP2E1 in deramciclane metabolism.	2005 Nov	15932955
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.	2008 Jan	17971064
Deramciclane improves object recognition in rats: potential role of NMDA receptors.	2010 Feb	19963003
Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein.	2010 Mar	19720112

Patents

Sample Use Guides

In Vivo Use Guide

60 mg/day

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 16 17:18:16 UTC 2022` Edited by `admin` on `Fri Dec 16 17:18:16 UTC 2022`
Record UNII	O5KFK61E74
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DERAMCICLANE

Official Name

English

deramciclane [INN]

Common Name

English

DERAMCICLANE [MI]

Common Name

English

Deramciclane [WHO-DD]

Common Name

English

Code System Code Type Description

INN

6838